Dalrada has completed a second clinical trial on its cerVIA cervical cancer screening kit. The study included 100 women from India between the ages of 31 and 65.
Results from the trial were published this month in the Indian Society of Perinatology and Reproductive Biology (IJOPARB) journal. Study participants were screened for cervical cancer with cerVIA, which showed an accuracy of 91%, according to the firm. The test is patent-pending, Dalrada said.